Brought to you by 
Cephalon acquires Sirtex; withdrawn
12 Nov 2020
Executive Summary
Cephalon's Australian business unit is acquiring Australian biotech Sirtex Medical (liver cancer therapies) for $A271mm ($160mm). It pays $A4.85 ($2.86) cash for each Sirtex share, which is a 2% premium to the average trading price the day before the deal's announcement.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cephalon acquires Sirtex; withdrawn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice